Samcheondang Pharm recorded a sharp decline during the trading session on the 8th, drawing market attention. As military tensions between the United States and Iran heighten uncertainties in the global financial market, strong selling pressure is emerging, particularly in bio and growth stocks.

On this day, Samcheondang Pharm's stock fell to 247,000 won during the session, dropping more than 15% compared to the previous trading day. Trading volume also increased significantly compared to usual, reflecting a heightened sense of caution among investors. Market analysts suggest that the ongoing instability in the Middle East is stimulating a risk-asset avoidance psychology. There are assessments that if U.S.-Iran tensions escalate, it could lead to higher international oil prices and inflationary pressures, prompting global investors to increase their cash positions rather than engage in aggressive investing.

The domestic stock market was not immune to this atmosphere. In the KOSDAQ market, profit-taking sell-offs flooded the market, centered around growth and tech stocks, and the bio sector also showed synchronized weakness. Stocks that had recently experienced significant gains saw strong profit-taking movements, leading to expanded volatility.

Samcheondang Pharm has recently been in the market's spotlight due to expectations for the development of an oral obesity treatment and the potential expansion of its biosimilar business. However, analysts note that in the short term, the combination of global stock market instability and shrinking investment sentiment is acting as a burden on the stock price.

During the session, the market is closely monitoring additional news related to the U.S. and Iran, international oil price trends, U.S. interest rate forecasts, and changes in foreign investor net purchases as key variables. In particular, there are forecasts that if geopolitical risks are prolonged, volatility could increase across the board for growth stocks, including bio stocks.

Meanwhile, some perspectives continue to focus on Samcheondang Pharm's mid-to-long-term business value. With major pipelines—such as treatments for eye diseases, biosimilars, and oral obesity treatments—still underway, evaluations suggest that the possibility of a recovery in investment sentiment cannot be ruled out once market anxiety eases.

The investment industry interprets the current phase as one dominated by a broader market risk-aversion psychology rather than individual corporate issues. Consequently, analysts suggest that short-term stock price trends may be more heavily influenced by global geopolitical situations and external variables than by individual corporate earnings.

[This article was written based on publicly available market data and provided price information, and utilized artificial intelligence (AI) technology in the process of drafting the article and organizing the information. The final content was produced after a review and editing process. The information provided in this article is intended for general investment information purposes and does not constitute a solicitation to invest in any specific stock or financial product. Investing in the stock and financial markets carries the risk of principal loss, and all responsibility for investments lies with the investor. Please be sure to check related disclosures and official materials before making investment decisions. This publication bears no legal or financial responsibility for the information provided.]